Abstract
The natriuretic peptide system (NPS) is intimately involved in cardiorenal homeostasis in health, and dysregulation of the NPS plays an important role in the pathophysiology of heart failure (HF). Indeed, the diuretic, vasorelaxation, beneficial remodeling, and potent neurohumoral inhibition of the NPS support the therapeutic development of chronic augmentation of the NPS in symptomatic HF. Further, chronic augmentation of the protective NPS and in early stages of HF may ultimately prevent the progression of HF and reduced subsequent morbidity and mortality. In the current manuscript, we review the rationale for as well as previous and current efforts aimed at chronic therapeutic augmentation of the NPS in HF.
Original language | English (US) |
---|---|
Pages (from-to) | 7-14 |
Number of pages | 8 |
Journal | Current heart failure reports |
Volume | 12 |
Issue number | 1 |
DOIs | |
State | Published - Jan 24 2015 |
Keywords
- Cyclic guanosine monophosphate (cGMP)
- Heart failure
- Natriuretic peptide
- Neprilysin
- Neutral endopeptidase
- Preclinical
ASJC Scopus subject areas
- Emergency Medicine
- Cardiology and Cardiovascular Medicine
- Physiology (medical)